Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by VestGen Advisors LLC

VestGen Advisors LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 121.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 4,870 shares of the pharmaceutical company’s stock after purchasing an additional 2,671 shares during the quarter. VestGen Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $2,546,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Capital Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $209,000. Sigma Investment Counselors Inc. grew its position in Vertex Pharmaceuticals by 7.9% in the third quarter. Sigma Investment Counselors Inc. now owns 9,806 shares of the pharmaceutical company’s stock worth $5,126,000 after buying an additional 717 shares during the last quarter. Victory Financial Group LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter valued at $255,000. Great Lakes Retirement Inc. boosted its position in shares of Vertex Pharmaceuticals by 6.0% in the 3rd quarter. Great Lakes Retirement Inc. now owns 2,265 shares of the pharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 129 shares during the period. Finally, Generali Asset Management SPA SGR raised its stake in Vertex Pharmaceuticals by 9.7% during the 3rd quarter. Generali Asset Management SPA SGR now owns 16,633 shares of the pharmaceutical company’s stock valued at $8,696,000 after purchasing an additional 1,472 shares during the period. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

VRTX opened at $540.00 on Friday. The business has a fifty day simple moving average of $522.84 and a 200 day simple moving average of $478.98. The company has a market capitalization of $137.05 billion, a PE ratio of 31.43, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 1 year low of $403.16 and a 1 year high of $560.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The firm had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the previous year, the business earned $4.52 EPS. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of analyst reports. The Goldman Sachs Group set a $653.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 1st. JPMorgan Chase & Co. initiated coverage on Vertex Pharmaceuticals in a report on Friday, September 11th. They set an “overweight” rating and a $560.00 target price on the stock. Leerink Partners initiated coverage on shares of Vertex Pharmaceuticals in a research report on Monday, September 21st. They set an “outperform” rating and a $594.00 target price on the stock. Wall Street Zen raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Finally, UBS Group boosted their price objective on shares of Vertex Pharmaceuticals from $585.00 to $615.00 and gave the stock a “buy” rating in a research report on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $579.81.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.